

TABLE 1.

Efficacy and Tolerability Outcomes						
Outcome	Study Visit					
	Baseline	Week 2	Week 4	Week 6	Week 8	Week 12
IGA score ^a	3	2	1	1	1	1
Treatment Success ^b	-	No	Yes	Yes	Yes	Yes
Affected BSA	10%	8%	5%	6%	5%	6%
Signs of Psoriasis (at target lesion) ^c						
Erythema	2	1	1	1	0	1
Plaque Elevation	4	0	1	1	1	1
Scaling	3	1	0	1	1	1
Local Skin Reactions ^d						
Itching	0	0	0	0	0	2
Dryness	2	0	0	0	2	1
Burning/Stinging	0	0	0	0	0	0

Face, scalp, palms, soles, groin, axillae, and intertriginous areas were excluded from assessment if psoriasis was present.

^aIGA based on a 5-point scale: 0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe.

^bTreatment success defined as a ≥ 2 -grade improvement from baseline in IGA score and a score of 'clear' or 'almost clear' (0 or 1).

^cSigns of psoriasis based on a 5-point scale: 0=none, 1=minimum, 2=mild, 3=moderate, 4=severe.

^dItching (within last 24 hours), dryness, and burning/stinging (within last 24 hours) based on a 4-point scale: 0=none, 1=mild, 2=moderate, 3=severe. BSA, body surface area; IGA, Investigator's Global Assessment.